¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer

Multiparametric magnetic resonance imaging (mpMRI) is the standard imaging modality for prostate cancer diagnosis and focal therapy planning. However, 10-20% of clinically significant prostate cancers (csPCa) are not visible on mpMRI (PI-RADS 1-2). These MRI-invisible lesions, typically identified only on systematic biopsy, are currently not targetable by MRI-guided focal therapy, leaving patients with the choice between whole-gland radical treatment or active surveillance. This prospective, multi-centre, single-arm phase II trial investigates whether pelvis-only ¹⁸F-PSMA-1007 positron emissio

Trial Details

NCT ID
NCT07788625
Phase
NA
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Focal Therapy for Prostate Cancer
Locations (sample)
  • Hong Kong, 香港島, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Men aged ≥50 years
  • Life expectancy \>10 years
  • Histologically confirmed localized prostate cancer, ISUP Grade Group 2 or 3
  • At least one clinically significant cancer focus (≥1 systematic biopsy core with Grade Group 2-3) that is MRI-invisible, defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →